Uniqure (NASDAQ:QURE) Posts Quarterly Earnings Results, Misses Estimates By $0.31 EPS
Uniqure (NASDAQ:QURE) announced its earnings results on Thursday. The biotechnology company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.31), MarketWatch Earnings reports. The firm had revenue of $1.54 million during the quarter, compared to analysts’ expectations of $17.87 million. Uniqure had a negative net margin of 2,553.30% and a negative return on equity of 42.00%.
Shares of NASDAQ QURE traded up $2.34 during mid-day trading on Friday, reaching $41.73. The company had a trading volume of 726,949 shares, compared to its average volume of 507,709. Uniqure has a twelve month low of $36.20 and a twelve month high of $76.69. The company has a debt-to-equity ratio of 0.12, a quick ratio of 12.89 and a current ratio of 12.89. The stock has a market capitalization of $1.85 billion, a PE ratio of -13.29 and a beta of 1.24. The stock’s 50 day moving average is $49.97 and its 200-day moving average is $55.53.
QURE has been the subject of several analyst reports. Credit Suisse Group restated a “buy” rating and issued a $76.00 target price on shares of Uniqure in a research note on Friday. Wells Fargo & Co downgraded shares of Uniqure from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $90.00 to $56.00 in a research note on Thursday, June 25th. Chardan Capital decreased their target price on shares of Uniqure from $105.00 to $80.00 and set a “buy” rating for the company in a research note on Thursday, June 25th. HC Wainwright reduced their price objective on shares of Uniqure from $73.00 to $64.00 and set a “buy” rating on the stock in a research note on Thursday, June 25th. Finally, Mizuho reiterated a “hold” rating and set a $61.00 price objective on shares of Uniqure in a research note on Tuesday, July 14th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and thirteen have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $73.92.
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.
Featured Article: What are some reasons analysts would give stocks a buy rating?
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.